The Phase 3 IMpower030 trial (NCT03456063) investigating atezolizumab (Tecentriq) in combination with chemotherapy for resectable non-small cell lung cancer (NSCLC) completed its primary data collection on 2025-10-01. This study evaluated neoadjuvant atezolizumab plus chemotherapy versus placebo plus chemotherapy, followed by adjuvant atezolizumab or best supportive care.
Background
Atezolizumab, also known as Tecentriq, is an engineered anti-PD-L1 antibody. This trial focused on its use in patients with resectable Stage II, IIIA, or select IIIB non-small cell lung cancer (NSCLC).
Trial design
The IMpower030 study (NCT03456063) is a Phase 3, randomized, double-blinded trial that enrolled 453 participants. The study investigated neoadjuvant atezolizumab or placebo, each in combination with platinum-based chemotherapy, for patients with resectable Stage II, IIIA, or select IIIB non-small cell lung cancer (NSCLC). Following neoadjuvant treatment, participants received open-label adjuvant/postoperative atezolizumab or best supportive care. The chemotherapy regimens included nab-paclitaxel, pemetrexed, and carboplatin.
What this means
The primary completion of the IMpower030 trial signifies that all planned primary data collection has concluded. Researchers will now proceed with the analysis of the collected data to evaluate the efficacy, safety, pharmacokinetics, and immunogenicity of atezolizumab in this neoadjuvant setting for resectable NSCLC. The results are anticipated to provide important insights into potential new treatment strategies for this patient population.
Source
The information regarding the primary completion of this trial was obtained from ClinicalTrials.gov, a public database of clinical studies. The update for study NCT03456063, titled "A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030)," was posted on 2025-10-01 on clinicaltrials.gov.